Association Between Statin Use Prior to Admission and Lower Coronavirus Disease 2019 (COVID-19) Severity in Patients With Cardiovascular Disease or Risk Factors.
Aged
Aged, 80 and over
COVID-19
/ diagnosis
Cardiovascular Diseases
/ diagnosis
Comorbidity
Databases, Factual
Dyslipidemias
/ diagnosis
Female
Heart Disease Risk Factors
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Japan
/ epidemiology
Male
Middle Aged
Patient Admission
Retrospective Studies
Risk Assessment
Severity of Illness Index
Time Factors
Cardiovascular risk factors
Coronavirus disease 2019 (COVID-19)
Statin
Journal
Circulation journal : official journal of the Japanese Circulation Society
ISSN: 1347-4820
Titre abrégé: Circ J
Pays: Japan
ID NLM: 101137683
Informations de publication
Date de publication:
25 05 2021
25 05 2021
Historique:
pubmed:
7
5
2021
medline:
3
6
2021
entrez:
6
5
2021
Statut:
ppublish
Résumé
Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19).Methods and Results:In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus. This study suggests the potential benefits of statins use against COVID-19.
Sections du résumé
BACKGROUND
Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19).Methods and Results:In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus.
CONCLUSIONS
This study suggests the potential benefits of statins use against COVID-19.
Identifiants
pubmed: 33952833
doi: 10.1253/circj.CJ-21-0087
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM